# Fady Hannah-Shmouni, MD FRCPC > Fady Hannah-Shmouni, MD FRCPC is a seed investor at Hormonaly backing Health Care and Blockchain. See 20 investments, check sizes, portfolio. Updated Aug 2026. - Type: Angel Investor - Fund: [Hormonaly](https://shizune.co/investors/profile/hormonaly) - Location: Dubai, United Arab Emirates - Total investments: 20 - Last investment: Jan 2024 - Lead investor: 25% - Last updated: Aug 2026 - LinkedIn: https://www.linkedin.com/in/fady-hannah-shmouni/ - X (Twitter): https://twitter.com/DrShmouni?ref_src=twsrc%5Egoogle%7Ctwcamp%5Eserp%7Ctwgr%5Eauthor - Website: http://www.shmouni.com Fady Hannah-Shmouni, MD FRCPC is a seed investor at Hormonaly in Dubai focused on Health Care and Blockchain. Fady Hannah-Shmouni, MD FRCPC, is a physician-investor and serial entrepreneur bridging the worlds of medicine and venture capital. A board-certified Endocrinologist & Metabolism specialist and Clinical Biochemical Geneticist, he trained at Yale University School of Medicine (Internal Medicine Residency, 2012–2015) and completed his Fellowshipat the National Institutes of Health (NIH, 2015–2017) and the University of Toronto (Clinical Biochemical Genetics, 2017–2018). He holds an MD from the University of Jordan School of Medicine (2003–2009).Fady serves as Managing Partner at FHS Capital (fhscapital.io), an early-stage venture capital and venture builder firm he co-founded, with 40+ companies funded across healthcare, AI, FinTech, CleanTech, and SaaS in North America and the MENA region. He is also Founder & CEO of Hormonaly.ai — the Evidence OS for peptide, hormone, and longevity medicine — an AI-powered clinical platform providing GRADE-rated evidence synthesis for clinicians worldwide. He is Founder and Chairman of Healthspan Digital Holdings Limited, and Assistant Clinical Professor at the University of British Columbia.Earlier, Fady served as Principal Investigator and Associate Investigator at the NICHD/NIH (2015–2021), where his research focused on cortisol and growth hormone dysregulation. He later served as Associate Program Director and Director of Graduate Medical Education at the NIH Endocrinology Fellowship Program (2019–2021), and as Founding Editor-in-Chief of Endocrine and Metabolic Science (Elsevier, 2019–2023). His research has contributed to 100+ peer-reviewed publications.His portfolio and advisory work includes Eli Health, Flyby, Science & Humans, Supernatural, Acorn Biolabs, NU, AI Nexus, Neurable, and DrVibe.ai, among others. In 2024, he joined the Faculty of the Geneva College of Longevity Science, and in 2025 became Director of its AI Academy. Fady is passionate about democratizing access to precision diagnostics, longevity medicine, and AI-driven healthcare innovation. ## Round sizes | Stage | Round size | | --- | --- | | Seed | $1M–$3.6M | | Pre-Seed | $573k–$600k | ## Investment focus ### Industry | Industry | Investments | Share | | --- | --- | --- | | Health Care | 5 | 25% | | Blockchain | 4 | 20% | | Artificial Intelligence | 4 | 20% | | Software | 3 | 15% | | Financial Services | 3 | 15% | 37 industries tracked in total. ### Stage | Stage | Investments | Share | | --- | --- | --- | | Seed | 8 | 40% | | Series A | 5 | 25% | | Pre-Seed | 4 | 20% | | Funding Round | 1 | 5% | | Venture - Series Unknown | 1 | 5% | ### Country | Country | Investments | Share | | --- | --- | --- | | United States | 7 | 35% | | Canada | 4 | 20% | | United Arab Emirates | 2 | 10% | | Ireland | 1 | 5% | | United Kingdom | 1 | 5% | 6 countries tracked in total. ## Investments | Company | Description | Amount | Stage | Date | Website | | --- | --- | --- | --- | --- | --- | | AI Nexus | AI Nexus Inc. is a deep tech company that develops groundbreaking artificial intelligence technologies designed for use in industry-specific subsidiaries. Based on decades of building AI solutions for military and civilian applications, AI Nexus has created an advanced AI platform that enables the creation of a diverse range of collaborative AIapplications across the AI spectrum. Most commercially available AI is focused on machine learning, a subfield of AI that is best suited to recognizing patterns but not understanding them. As there is no understanding, machine learning can’t explain its thinking so can’t be given autonomy in complex life-or-death situations. Our technology can embody different AI techniques, algorithms and software from any source, can run autonomously in devices like IoT all the way up to the cloud (allows you to use whatever is out there).AI applications built with our technology will be able to observe the world, reason, make recommendations and even take autonomous action. Software that can sense, reason, act & learn | | Series A | Jan 01, 2024 | | | Healthspan Digital | | | Pre-Seed | Jun 01, 2023 | | | Eli | Eli empowers women to understand their body and the transitions it goes through every day, and across life. We develop a device that uses saliva to capture hormone fluctuations at home, and an app that gives women the information they want to own their health decisions. | $3.6M | Seed | Apr 04, 2023 | | | FLUUS | FLUUS is an aggregator of fiat to crypto gateways with a crypto ramping network covering emerging. FLUUS allows users to buy, sell, or swap cryptocurrencies and tokens. They aggregate cryptographic services into a single software development kit, connect ramping, exchanging, transactions, and payments, and create a money experience. | $600K | Pre-Seed | Feb 28, 2023 | | | Flyby | Flyby connects digital out-of-home advertising with last-mile delivery. | $1M | Seed | Jan 13, 2023 | | | Jung+ Longevity | Jung+ operates in the biotechnology industry, focusing on translating the latest scientific advancements into products and technologies aimed at slowing aging and extending healthy lifespan. The company leverages a deep understanding of the 12 Hallmarks of Aging, a scientific framework that maps the root causes of biological aging, to develop itsTotal Longevity System™. This system is designed to offer long-term, synergistic effects to users, incorporating various products engineered for enhancing lifespan and health. Jung+ is committed to bringing scientific insights into practical applications, making the benefits of anti-aging research accessible to a broader audience. | $572.5K | Pre-Seed | Jan 01, 2023 | | | FirstHx | FirstHx is a knowledge-based history taking solution that helps patients communicate their medical histories to their health care team. | | Seed | Jan 01, 2023 | | | Homecare Hub | Homecare Hub assists persons with caregiving needs, such as those with dementia, disability, accident, fall risk, or chronic illness, in avoiding huge institutional nursing facilities, by offering a superior experience in a secure, individualized, inexpensive, small shared care and co-living environment. To help people locate home care servicesthat are reasonably priced, it offers home health care services. With the help of the company's services, customers may locate reliable care for their loved ones in the areas of personal care, companion care, live-in care, home support, and many more. | | Seed | Jan 01, 2023 | | | W3box | W3box is an advanced automation platform that streamlines the monetization of digital assets and the use of smart contracts. This means our clients can easily pick and choose the specific features they require, tailoring the solution to their needs. The underlying technology of our blockchain solution is secure, but also consistently reliable andcapable of scaling to meet the demands of large enterprise-level web3 applications. While our platform is robust enough for corporate use, it's also user-friendly for everyday consumers. Among our groundbreaking features, we're pioneering innovations in On-Chain File creation and storage, as well as providing enhanced insights for supply chain management and beyond. | | Seed | Jan 01, 2023 | | | Fasset | Fasset is a global digital asset gateway that brings unparalleled accessibility to the digital asset space. Through our simple, safe and innovative digital assets, we provide people in emerging markets the opportunity to build a better future. We are pioneering web3 technologies and driving adoption of digital assets for the next billion. | | Series A | Oct 01, 2022 | | 10 of 20 investments shown. ## Co-investors - [FHS Capital](https://shizune.co/investors/profile/fhs-capital) — VC Fund, 4 deals together - [VN2 Capital](https://shizune.co/investors/profile/vn2-capital) — VC Fund, 2 deals together - [Cake Ventures](https://shizune.co/investors/profile/cake-ventures) — VC Fund, 1 deal together - [Encryptus Capital](https://shizune.co/investors/profile/encryptus-capital) — VC Fund, 1 deal together - [Fatima Gobi Ventures](https://shizune.co/investors/profile/fatima-gobi-ventures) — VC Fund, 1 deal together - [Formus Capital](https://shizune.co/investors/profile/formus-capital) — VC Fund, 1 deal together ## About Hormonaly VC Fund 1 contacts available at Hormonaly. | Name | Title | Profile | | --- | --- | --- | | Fady Hannah-Shmouni, MD FRCPC | Founder, CEO & CBO | https://shizune.co/investors/profile/fady-hannah-shmouni-f393 | ## Similar investors ### Similar industry - [Antler](https://shizune.co/investors/profile/antler-be9c) — VC Fund - [Forerunner](https://shizune.co/investors/profile/forerunner-ventures) — VC Fund - [Right Side Capital Management](https://shizune.co/investors/profile/right-side-capital-management) — VC Fund ### Similar stage - [Antler](https://shizune.co/investors/profile/antler-be9c) — VC Fund - [Alumni Ventures](https://shizune.co/investors/profile/alumni-ventures-group) — VC Fund - [Right Side Capital Management](https://shizune.co/investors/profile/right-side-capital-management) — VC Fund ### Similar country - [Wamda Capital](https://shizune.co/investors/profile/wamda) — VC Fund - [F6 Ventures](https://shizune.co/investors/profile/flat6labs) — VC Fund - [Shorooq Partners](https://shizune.co/investors/profile/shorooq-partners) — VC Fund ## Featured in investor lists - [Health Care Angel Investors in Canada](https://shizune.co/investors/health-care-angel-investors-canada) - [All Angel Investors in United Arab Emirates](https://shizune.co/investors/angel-investors-united-arab-emirates) - [Web3 Angel Investors in United Kingdom](https://shizune.co/investors/web3-angel-investors-united-kingdom) - [Blockchain Angel Investors in United Kingdom](https://shizune.co/investors/blockchain-angel-investors-united-kingdom) - [Digital Media Angel Investors in Middle East](https://shizune.co/investors/digital-media-angel-investors-middle-east) - [Enterprise Angel Investors in United Arab Emirates](https://shizune.co/investors/enterprise-angel-investors-united-arab-emirates) ## FAQ ### What does Fady Hannah-Shmouni, MD FRCPC invest in? Fady Hannah-Shmouni, MD FRCPC invests primarily in Health Care, Blockchain and Artificial Intelligence startups, most often at Seed and Series A stage. Most of the 20 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio. ### What is Fady Hannah-Shmouni, MD FRCPC's check size? Fady Hannah-Shmouni, MD FRCPC typically joins rounds of $1M–$3.6M at Seed and $573k–$600k at Pre-Seed. These ranges are 10th–90th percentile round sizes calculated from confirmed public funding rounds, so they are a realistic guide to the rounds Fady Hannah-Shmouni, MD FRCPC participates in. ### When did Fady Hannah-Shmouni, MD FRCPC last invest? The most recent investment recorded for Fady Hannah-Shmouni, MD FRCPC closed in Jan 2024. Shizune tracks 20 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly. ### Is Shizune's investor data accurate? Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page. # About Shizune Shizune.co is an investor database. Core features: - 48,091 startup investors (angels, VCs, accelerators, and others) - Email, phone, LinkedIn (for intros), socials, and other contact data - Updated daily from public funding news - CSV and Excel export The User can access the full database FOR FREE after signing up: shizune.co